Journal
DRUG DELIVERY
Volume 29, Issue 1, Pages 186-191Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2021.2005719
Keywords
Nano-radiotherapy; nano-radium; radium dichloride ([Ra-223] RaCl2) Nanoemulsion; nanomicelles; cancer; bone
Categories
Funding
- CNPq [301069/2018-2]
- FAPERJ (Rede NanoSaude)
- CAPES (PROEXT-PPGB-UERJ)
- UFMA
Ask authors/readers for more resources
Radium dichloride ([Ra-223] RaCl2) nanomicelles have shown superior therapeutic effects compared to pure radium dichloride ([Ra-223] RaCl2), validating the feasibility of nanotechnology in alpha-radiotherapy.
The treatment of bone metastatsis as primary bone cancer itself is still a challenge. The use od radium dichloride ([Ra-223] RaCl2) has emerged in the last few years as one of the best treatment choice for bone cancer, with especial focus in bone metastasis. The alpha-emitter radiopharmaceutical has showed potent and efficient results in several clinical trials. In this study we have formulated radium dichloride ([Ra-223] RaCl2) nanomicelles in order to evaluate and compare with pure radium dichloride ([Ra-223] RaCl2). The results showed that nanomicelles at the same dose had a superior effect (20% higher efficient) when compared with pure radium dichloride ([Ra-223] RaCl2). The results corroborated the effectiveness of the nanosystem validating the application of nanotechnology in alpha-radiotherapy with radium dichloride ([Ra-223] RaCl2).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available